Tag: #LAM
Liquid Biopsy Platform Demonstrates High Diagnostic Capabilities In Early Stages of Nasopharyngeal Carcinoma
| Onco'Zine

Commercial-stage medical technology company Laboratory for Advanced Medicine (LAM) announced positive results from a new study that evaluated DNA methylation-based marker panel for early diagnosis of nasopharyngeal carcinoma (NPC). The data will be presented in an online only abstract as part of the annual meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, Ill., May […]

DNA Methylation Analysis for Early Detection of Various Cancers
| Technology Networks

When a cancer cell dies, its DNA is released into the blood. Once released this DNA is referred to as cell-free DNA (cfDNA). The cfDNA retains a DNA methylation pattern that corresponds to the cell it originated from. When a “normal” cell transforms into a cancer cell significant gene expression changes occur, and these alterations […]

Guardant to develop CDx and TMB liquid biopsy tests for AstraZeneca’s targeted cancer therapies
| Fierce Biotech

AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi. Under the multiyear agreement, Guardant will pursue an FDA approval for a Guardant360 CDx liquid biopsy test to help identify non-small cell lung cancer patients for treatment with Tagrisso, an EGFR inhibitor.